Report Explores Future of Opioid Abuse-Resistant Formulations
A GBI Research report says the opioid market will be driven by development of new products and post-marketing studies designed to reduce abuse risk.
A new report from GBI Research reviews the current opioid-product market, analyzes the development pipeline, and reviews industry merger, acquisition, and licensing deals to develop a picture of the market through 2018. The increase in opioid use has led to an increase in abuse and consequently to increasing concern from doctors and regulators. As a result, approved drugs are differentiated increasingly by abuse-resistant technologies.
Many companies are working to develop abuse-resistant formulations of extended-release (ER) opioid analgesics, notes GBI Research. Most recent marketing approvals for ER opioids in the US have included risk evaluation and mitigation strategies that require license holders to provide physician training and raise patient awareness of opioid abuse. In many cases, post-marketing studies are required to examine the efficacy of abuse-resistant formulations. Initial post-marketing data reports for Embeda, which was launched in the US in 2009, are positive.
The current opioids market has a broad and highly diversified product profile, reports GBI Research. The developmental pipeline is small, however, and the market is relatively stagnant. Competition among abuse-resistant products is expected to be the driving factor in this market.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
